

LETTER

Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation

We read with interest the work by Weber *et al*¹ reporting that severe liver failure was observed in a patient during SARS-CoV-2 infection. They suggested that close monitoring of liver function is necessary, and further investigation is required to elucidate the risk factors for liver failure in patients with COVID-19. Previous studies have indicated that liver injury could affect the prognosis of patients with COVID-19, and mortality rate was significantly increased in patients with severe liver injury.^{2,3} However, the risk factors in patients with COVID-19 developing severe liver injury during hospitalisation have not been thoroughly investigated. Thus, in this study, patients with COVID-19 were recruited to identify

the risk factors in patients with COVID-19 with severe liver injury.

A total of 192 patients diagnosed with COVID-19 were consecutively hospitalised at Chongqing Public Health Medical Center from January to March 2020, and 12 patients with existing liver disease had been excluded in this study. Liver injury was detected in 75 (39.06%) enrolled patients at admission and 133 (69.27%) during hospitalisation, respectively. Interestingly, liver injury was observed in 25 out of 29 (86.21%) patients with severe COVID-19. In consistence with our findings, Qi *et al*⁴ revealed that 45.71% of the patients had liver injury at admission; furthermore, Fan *et al*⁵ reported that 48.4% of the patients with normal liver function developed liver injury during hospitalisation, suggesting that a high percentage of patients with COVID-19 have liver injury.

Therefore, identification of the risk factors contributing to severe liver injury during hospitalisation is essential for the treatment of COVID-19. The results indicated that the number of T lymphocyte

subsets (CD3⁺, CD4⁺ and CD8⁺ T cells) were significantly reduced in patients with severe liver injury, while the proportion of ritonavir, the number of neutrophils and monocytes, and the production of IL-6 and IL-10 were remarkably increased (online supplementary table 1). Univariate analysis indicated that ritonavir, CD3⁺, CD4⁺ and CD8⁺ T cells, IL-6 and IL-10 were potential risk factors in patients with COVID-19 with severe liver injury during hospitalisation ($p < 0.05$, table 1); multivariate analysis revealed that ritonavir (OR 5.63, 95% CI 2.86 to 18.63, $p < 0.001$), IL-6 (OR 2.21, 95% CI 1.09 to 4.67, $p = 0.006$), IL-10 (OR 1.78, 95% CI 1.08 to 3.12, $p = 0.014$) and CD4⁺ T cells (OR 3.24, 95% CI 1.05 to 6.38, $p < 0.001$) were independent risk factors in patients with COVID-19 with severe liver damage (table 1), suggesting that the progression of liver injury was associated with medication, T lymphocyte subsets and inflammatory cytokines.

SARS-CoV-2-mediated liver injury might be a key factor in liver damage.⁶ SARS-CoV-2 may directly target ACE2-

Table 1 Identification of putative risk factors in patients with COVID-19 developing severe liver injury during hospitalisation

Variable	Univariable OR (95% CI)	P value	Multivariable OR (95% CI)	P value
Ritonavir	5.24 (0.69 to 16.39)	<0.001	5.63 (2.86 to 18.63)	<0.001
IL-6, pg/mL	2.13 (1.08 to 3.21)	<0.001	2.21 (1.09 to 4.67)	0.006
IL-10, pg/mL	1.82 (1.03 to 2.85)	0.004	1.78 (1.08 to 3.12)	0.014
CD4 ⁺ T cell, per μ L	2.90 (1.85 to 5.96)	<0.001	3.24 (1.05 to 6.38)	<0.001
CD8 ⁺ T cell, per μ L	1.88 (1.03 to 3.15)	0.005		
CD4 ⁺ T/CD8 ⁺ T cell	1.08 (0.99 to 1.35)	0.163		
CD3 ⁺ T cell, per μ L	0.43 (0.19 to 0.88)	0.034		
Neutrophil count, $\times 10^9/L$	1.11 (1.02 to 1.25)	0.077		
Monocyte count, $\times 10^9/L$	3.41 (1.05 to 17.99)	0.106		




Figure 1 Host immune responses and potential liver injury during the viral infection of SARS-CoV-2.

positive cholangiocytes and hepatocytes, further leading to liver cell damage and bile duct cell dysfunction, consequently aggravating liver damage. Dysregulated immune response was observed in patients with COVID-19.⁷ Furthermore, previous studies have indicated that the SARS-CoV-2 infection may primarily affect T lymphocytes, particularly CD4⁺ and CD8⁺ cells, which are involved in pro-inflammatory responses.^{7,8} At present, no specific treatment is available for patients with COVID-19. The commonly used antiviral drugs lopinavir/ritonavir are mainly metabolised in the liver but exhibit side effects such as liver dysfunction. In addition, overdose of ribavirin induces hemolysis and exacerbates tissue hypoxia, leading to the elevation of serum

liver enzymes.^{9 10} A recent study revealed higher proportion in patients with liver dysfunction following the treatment with lopinavir/ritonavir during hospitalisation.⁵

In conclusion, potential risk factors in patients with COVID-19 developing severe liver injury were ritonavir, elevated IL-6 and IL-10, and reduced CD4⁺ T cells. In addition, the underlying mechanisms of liver injury in patients with COVID-19 involve immune response, cytokine production, drug-induced liver injury and potential SARS-CoV-2-mediated liver damage (figure 1). Therefore, during the treatment of COVID-19, liver function, inflammatory cytokines and T lymphocyte subsets should be closely monitored, and drug-induced liver damage could be considered in clinical practice.

Ke Zhan,¹ Shengtao Liao,¹ Jinfang Li,² Yang Bai,³ Lin Lv,¹ Keqi Yu,¹ Liwang Qiu,^{1,4} Chuanfei Li,¹ Guodan Yuan,⁵ An Zhang,⁶ Zhechuan Mei¹

¹Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

²Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

³Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

⁴Department of Gastroenterology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China

⁵Department of Critical Care Medicine, Chongqing Public Health Medical Center, Chongqing, China

⁶Department of Critical Care Medicine, Chongqing Medical University Affiliated Second Hospital, Chongqing, China

Correspondence to Professor Zhechuan Mei, Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China; meizhechuan@cqmu.edu.cn, Professor An Zhang, Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China; zhangana@hospital.cqmu.edu.cn and Dr Guodan Yuan,

Department of Critical Care Medicine, Chongqing Public Health Medical Center, Chongqing 400036, China; 71502294@qq.com

Contributors ZM, AZ, GY and SL initiated and designed the study. KZ, JL, LL, KY, LQ and CL collected the data. KZ, SL and YB analysed the data. KZ, SL and JL wrote the letter. SL drafted the figure. ZM, AZ and GY reviewed and edited the letter. All authors read and approved the final version for publication.

Funding This work was supported by the Chongqing Special Research Project for Prevention and Control of COVID-19 (grant no. cstc2020jcsx-fyzx0103).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval Chongqing Public Health Medical Center (2020-025-KY).

Provenance and peer review Not commissioned; externally peer reviewed.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2020-321913>).

KZ and SL are joint first authors.



To cite Zhan K, Liao S, Li J, *et al.* Gut Epub ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2020-321913

Received 21 May 2020

Revised 12 June 2020

Accepted 13 June 2020

Gut 2020;0:1–2. doi:10.1136/gutjnl-2020-321913

ORCID iD

Zhechuan Mei <http://orcid.org/0000-0001-9766-3684>

REFERENCES

- Weber S, Mayerle J, Irlbeck M, *et al.* Severe liver failure during SARS-CoV-2 infection. *Gut* 2020;69:1365–7.
- Qi X, Liu Y, Wang J, *et al.* Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study [published online ahead of print, 2020 May 20]. *Gut* 2020.
- Lei F, Liu Y-M, Zhou F, *et al.* Longitudinal association between markers of liver injury and mortality in COVID-19 in China. *Hepatology* 2020. doi:10.1002/hep.31301. [Epub ahead of print: 02 May 2020].
- Qi X, Liu C, Jiang Z, *et al.* Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. *J Hepatol* 2020. doi:10.1016/j.jhep.2020.04.010. [Epub ahead of print: 17 Apr 2020].
- Fan Z, Chen L, Li J, *et al.* Clinical features of COVID-19-related liver functional abnormality. *Clin Gastroenterol Hepatol* 2020;18:1561–6.
- Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. *Lancet Gastroenterol Hepatol* 2020;5:529–30.
- Ong EZ, Chan YFZ, Leong WY, *et al.* A dynamic immune response shapes COVID-19 progression. *Cell Host Microbe* 2020;27:879–82.
- Maggi E, Canonica GW, Moretta L. COVID-19: unanswered questions on immune response and pathogenesis. *J Allergy Clin Immunol* 2020. doi:10.1016/j.jaci.2020.05.001. [Epub ahead of print: 08 May 2020].
- Hung IF-N, Lung K-C, Tso EY-K, *et al.* Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* 2020;395:1695–704.
- Cai Q, Huang D, Yu H, *et al.* COVID-19: abnormal liver function tests. *J Hepatol* 2020.